placeholder

Byron C. Jaeger, PhD,1

1Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC.

Table: Exclusions

| **Inclusion criteria** | **Total** | **2013-2014** | **2015-2016** | **2017-2020** |
| --- | --- | --- | --- | --- |
| NHANES participants from 2013-2020 | 35,706 | 10,175 | 9,971 | 15,560 |
| Completed the interview and examination | 33,657 | 9,813 | 9,544 | 14,300 |
| Age 30-79 years | 15,235 | 4,337 | 4,200 | 6,698 |
| No history of CVD | 13,582 | 3,922 | 3,756 | 5,904 |
| Have information on SBP, DBP and self-reported antihypertensive medication use | 12,743 | 3,785 | 3,639 | 5,319 |
| Have information on other variables in the PCEs and PREVENT equations | 11,948 | 3,581 | 3,423 | 4,944 |

Table 1. Characteristics of US adults by blood pressure levels and antihypertensive medication use based on the 2013-2020 National Health and Nutrition Examination Survey.

|  | **SBP/DBP categories in mm Hg among US adults not taking antihypertensive medication** | | | | **Taking antihypertensive medication (n = 36.6M)** |
| --- | --- | --- | --- | --- | --- |
| **Characteristic†** | **<120/80 (n = 56.0M)** | **120-129/<80 (n = 19.7M)** | **130-139/80-89 (n = 22.3M)** | **≥140/90 (n = 14.7M)** |
| % (95% CI) of US population | 37.5 (36.1, 38.9) | 13.2 (12.2, 14.3) | 14.9 (13.9, 16.0) | 9.87 (8.95, 10.9) | 24.5 (23.2, 25.8) |
| Age, years | 44.9 (44.3, 45.6) | 50.1 (49.3, 51.0) | 49.6 (48.8, 50.4) | 54.3 (53.5, 55.1) | 59.0 (58.5, 59.6) |
| Men | 40.6 | 57.9 | 54.4 | 58.1 | 44.9 |
| Race/ethnicity, % | | | | | |
| Non-Hispanic White | 66.3 | 66.0 | 65.9 | 62.1 | 67.6 |
| Non-Hispanic Black | 7.14 | 8.47 | 10.2 | 13.6 | 14.3 |
| Non-Hispanic Asian | 6.63 | 4.75 | 5.83 | 5.62 | 4.68 |
| Hispanic | 16.3 | 17.9 | 15.2 | 14.9 | 10.6 |
| Other | 3.68 | 2.88 | 2.81 | 3.81 | 2.86 |
| Cigarette smoking, % | 17.2 | 18.7 | 17.4 | 20.2 | 16.8 |
| Total cholesterol, mg/dL | 193 (191, 195) | 199 (196, 201) | 203 (199, 207) | 208 (204, 211) | 192 (190, 195) |
| HDL cholesterol, mg/dL | 56.4 (55.5, 57.4) | 54.1 (52.9, 55.3) | 53.6 (52.5, 54.6) | 54.9 (53.1, 56.7) | 53.0 (52.2, 53.8) |
| Non-HDL cholesterol, mg/dL | 137 (135, 138) | 145 (142, 147) | 149 (146, 153) | 153 (150, 156) | 139 (137, 142) |
| Statin use, % | 0.08 (0.07, 0.09) | 0.12 (0.10, 0.14) | 0.10 (0.08, 0.12) | 0.12 (0.09, 0.14) | 0.40 (0.37, 0.43) |
| HbA1c, % | 5.44 (5.41, 5.47) | 5.65 (5.58, 5.72) | 5.71 (5.64, 5.77) | 5.80 (5.71, 5.89) | 6.04 (6.00, 6.08) |
| Diabetes, % | 4.66 | 8.59 | 8.51 | 11.9 | 26.1 |
| eGFR, ml/min/1.73 m2 | 99.3 (98.3, 100) | 95.4 (94.2, 96.5) | 96.2 (94.9, 97.4) | 93.1 (91.8, 94.5) | 85.9 (85.0, 86.7) |
| eGFR < 60 ml/min/1.73 m2, % | 1.27 | 2.05 | 1.68 | 4.31 | 10.7 |
| Albumin-to-creatinine ratio, mg/g | 13.4 (11.3, 15.5) | 16.1 (10.7, 21.6) | 21.9 (16.2, 27.5) | 50.0 (36.5, 63.5) | 58.1 (42.7, 73.5) |
| Albumin-to-creatinine ratio > 30 mg/g | 5.10 | 4.92 | 8.11 | 15.4 | 14.7 |
| Systolic blood pressure, mm Hg | 110 (109, 110) | 124 (124, 125) | 129 (129, 130) | 149 (148, 150) | 131 (130, 132) |
| Diastolic blood pressure, mm Hg | 67.1 (66.8, 67.5) | 71.1 (70.6, 71.5) | 79.3 (78.8, 79.9) | 84.2 (83.1, 85.2) | 73.0 (72.4, 73.6) |
| †Population characteristics in the table are percentage or mean (95% confidence interval). US adults were grouped into the higher category of systolic and diastolic blood pressure. For example, if a person had systolic blood pressure of 146 mm Hg and diastolic blood pressure of 82 mm Hg, they were grouped into the ≥140/90 mm Hg category. | | | | | |
| SBP – systolic blood pressure; DBP – diastolic blood pressure; eGFR - estimated glomerular filtration rate. | | | | | |

Table 2. Ten-year predicted cardiovascular disease risk by blood pressure levels and antihypertensive medication use based on the 2013-2020 National Health and Nutrition Examination Survey.

|  | **SBP/DBP categories in mm Hg among US adults not taking antihypertensive medication** | | | | **Taking antihypertensive medication** |
| --- | --- | --- | --- | --- | --- |
| **Mean (95% CI) 10-year predicted risk** | **<120/80** | **120-129/<80** | **130-139/80-89** | **≥140/90** |
| ASCVD | | | | | |
| Pooled cohort equations | 2.56 (2.35, 2.78) | 5.53 (5.01, 6.04) | 5.48 (5.05, 5.90) | 10.3 (9.53, 11.1) | 13.5 (12.9, 14.0) |
| PREVENT base equation | 1.52 (1.42, 1.63) | 2.97 (2.75, 3.20) | 2.96 (2.78, 3.14) | 5.41 (5.10, 5.73) | 6.90 (6.67, 7.14) |
| PREVENT full equation | 1.28 (1.19, 1.36) | 2.51 (2.31, 2.70) | 2.57 (2.39, 2.75) | 4.79 (4.45, 5.14) | 5.95 (5.73, 6.17) |
| Total CVD | | | | | |
| PREVENT base equation | 2.46 (2.28, 2.64) | 4.69 (4.34, 5.05) | 4.60 (4.29, 4.92) | 8.56 (8.04, 9.07) | 12.3 (11.9, 12.7) |
| PREVENT full equation | 2.03 (1.88, 2.17) | 3.88 (3.57, 4.18) | 3.94 (3.65, 4.24) | 7.46 (6.89, 8.03) | 10.6 (10.2, 11.0) |

Table 3. Distribution of 10-year predicted risk by blood pressure levels and antihypertensive medication use based on the 2013-2020 National Health and Nutrition Examination Survey.

|  | **SBP/DBP categories in mm Hg among US adults not taking antihypertensive medication** | | | | **Taking antihypertensive medication** |
| --- | --- | --- | --- | --- | --- |
| **10-year risk categories, %** | **<120/80** | **120-129/<80** | **130-139/80-89** | **≥140/90** |
| Pooled cohort equations - ASCVD | | | | | |
| <5% | 85.0 | 64.6 | 64.6 | 37.5 | 27.7 |
| 5% to <10% | 9.66 | 18.6 | 19.1 | 24.7 | 23.0 |
| 10% to <15% | 3.18 | 6.78 | 8.19 | 13.7 | 15.6 |
| ≥ 15% | 2.13 | 9.96 | 8.07 | 24.2 | 33.7 |
| PREVENT base equation - ASCVD | | | | | |
| <5% | 94.4 | 81.8 | 82.8 | 57.7 | 43.0 |
| 5% to <10% | 4.28 | 14.7 | 13.4 | 28.1 | 34.1 |
| 10% to <15% | 1.27 | 2.90 | 3.27 | 10.5 | 16.1 |
| ≥ 15% | 0.04 | 0.60 | 0.53 | 3.78 | 6.88 |
| PREVENT full equation - ASCVD | | | | | |
| <5% | 96.0 | 85.5 | 86.8 | 65.2 | 53.0 |
| 5% to <10% | 3.42 | 12.1 | 10.8 | 23.9 | 29.6 |
| 10% to <15% | 0.56 | 2.20 | 1.64 | 8.12 | 13.1 |
| ≥ 15% | 0.01 | 0.22 | 0.83 | 2.77 | 4.34 |
| PREVENT base equation - Total CVD | | | | | |
| <5% | 87.0 | 67.0 | 68.4 | 38.3 | 23.2 |
| 5% to <10% | 8.78 | 18.6 | 20.5 | 30.0 | 25.1 |
| 10% to <15% | 2.30 | 9.96 | 6.82 | 15.1 | 19.9 |
| ≥ 15% | 1.90 | 4.47 | 4.20 | 16.6 | 31.8 |
| PREVENT full equation - Total CVD | | | | | |
| <5% | 89.9 | 75.3 | 76.0 | 47.6 | 29.7 |
| 5% to <10% | 7.04 | 15.6 | 15.4 | 28.7 | 28.5 |
| 10% to <15% | 1.90 | 5.90 | 5.33 | 10.9 | 17.5 |
| ≥ 15% | 1.16 | 3.19 | 3.26 | 12.8 | 24.3 |

Table 4. Cross-categorization of 10-year predicted risk by the PREVENT and pooled cohort equations based on the 2013-2020 National Health and Nutrition Examination Survey.

|  | | **SBP/DBP categories in mm Hg among US adults not taking antihypertensive medication** | | | | **Taking antihypertensive medication** |
| --- | --- | --- | --- | --- | --- | --- |
| **PREVENT** | **PCE** | **<120/80** | **120-129/<80** | **130-139/80-89** | **≥140/90** |
| PREVENT base equation - Total CVD | | | | | | |
| < 10% | < 10% | 94.2 | 82.0 | 82.7 | 59.9 | 43.6 |
| ≥ 10% | < 10% | 0.49 | 1.23 | 1.00 | 2.26 | 7.08 |
| < 10% | ≥ 10% | 1.61 | 3.55 | 6.24 | 8.43 | 4.71 |
| ≥ 10% | ≥ 10% | 3.70 | 13.2 | 10.0 | 29.4 | 44.6 |
| PREVENT full equation - ASCVD | | | | | | |
| < 10% | < 10% | 94.7 | 83.2 | 83.7 | 61.8 | 50.4 |
| ≥ 10% | < 10% | 0.02 | 0.04 | 0.00 | 0.37 | 0.27 |
| < 10% | ≥ 10% | 4.02 | 13.3 | 12.5 | 24.0 | 26.6 |
| ≥ 10% | ≥ 10% | 1.30 | 3.47 | 3.80 | 13.9 | 22.7 |
| PREVENT base equation - Total CVD | | | | | | |
| < 15% | < 10% | 94.6 | 83.2 | 83.6 | 61.7 | 49.7 |
| ≥ 15% | < 10% | 0.04 | 0.04 | 0.10 | 0.41 | 0.98 |
| < 15% | ≥ 10% | 3.46 | 12.3 | 12.2 | 21.7 | 18.5 |
| ≥ 15% | ≥ 10% | 1.86 | 4.43 | 4.10 | 16.2 | 30.8 |

Table X. Characteristics of US adults with SBP of 130-139 mm Hg or DBP of 80-89 mm Hg by predicted risk use based on the 2013-2020 National Health and Nutrition Examination Survey. USE TOTAL CVD FOR PREVENT AND ASCVD FOR PCE

|  |  |  |  |
| --- | --- | --- | --- |
|  | PCE ≥ 10%  Prevent <15%  (n=278) | PCE ≥ 10%  Prevent ≥15%  (n=96) | Prevalence ratio |
| Age, years |  |  |  |
| Men |  |  |  |
| Race/ethnicity |  |  |  |
| Non-Hispanic White |  |  | 1 (ref) |
| Non-Hispanic Black |  |  |  |
| Non-Hispanic Asian |  |  |  |
| Hispanic |  |  |  |
| Other |  |  |  |
| Cigarette smoking, % |  |  |  |
| Total cholesterol, mg/dL |  |  |  |
| HDL cholesterol, mg/dL |  |  |  |
| Non-HDL cholesterol, mg/dL |  |  |  |
| Statin use, % |  |  |  |
| HbA1c, % |  |  |  |
| Diabetes, % |  |  |  |
| eGFR, ml/min/1.73 m2 |  |  |  |
| eGFR < 60 ml/min/1.73 m2, % |  |  |  |
| Albumin-to-creatinine ratio, mg/g |  |  |  |
| Albumin-to-creatinine ratio > 30 mg/g |  |  |  |
| Systolic blood pressure, mm Hg |  |  |  |
| Diastolic blood pressure, mm Hg |  |  |  |

Table X. Characteristics of US adults by BP category and predicted risk use based on the 2013-2020 National Health and Nutrition Examination Survey.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | SBP < 120 mm Hg and  DBP < 80 mm Hg | | SBP of 120-129 mm Hg  DBP < 80 mm Hg | | SBP ≥140 mm Hg or  DBP ≥ 90 mm Hg | | Taking antihypertensive medications | |
|  | PCE ≥ 10%  Prevent <15%  (n=) | PCE ≥ 10%  Prevent ≥15%  (n=) | PCE ≥ 10%  Prevent <15%  (n=) | PCE ≥ 10%  Prevent ≥15%  (n=) | PCE ≥ 10%  Prevent <15%  (n=) | PCE ≥ 10%  Prevent ≥15%  (n=) | PCE ≥ 10%  Prevent <15%  (n=) | PCE ≥ 10%  Prevent ≥15%  (n=) |
| Age, years |  |  |  |  |  |  |  |  |
| Men |  |  |  |  |  |  |  |  |
| Race/ethnicity |  |  |  |  |  |  |  |  |
| Non-Hispanic White |  |  |  |  |  |  |  |  |
| Non-Hispanic Black |  |  |  |  |  |  |  |  |
| Non-Hispanic Asian |  |  |  |  |  |  |  |  |
| Hispanic |  |  |  |  |  |  |  |  |
| Other |  |  |  |  |  |  |  |  |
| Cigarette smoking, % |  |  |  |  |  |  |  |  |
| Total cholesterol, mg/dL |  |  |  |  |  |  |  |  |
| HDL cholesterol, mg/dL |  |  |  |  |  |  |  |  |
| Non-HDL cholesterol, mg/dL |  |  |  |  |  |  |  |  |
| Statin use, % |  |  |  |  |  |  |  |  |
| HbA1c, % |  |  |  |  |  |  |  |  |
| Diabetes, % |  |  |  |  |  |  |  |  |
| eGFR, ml/min/1.73 m2 |  |  |  |  |  |  |  |  |
| eGFR < 60 ml/min/1.73 m2, % |  |  |  |  |  |  |  |  |
| Albumin-to-creatinine ratio, mg/g |  |  |  |  |  |  |  |  |
| Albumin-to-creatinine ratio > 30 mg/g |  |  |  |  |  |  |  |  |
| Systolic blood pressure, mm Hg |  |  |  |  |  |  |  |  |
| Diastolic blood pressure, mm Hg |  |  |  |  |  |  |  |  |